Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 145,445 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Osteogenesis Imperfecta
Interventions: Risedronate Oral Tablet; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 6 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Pruritus, Uremic Pruritus
Interventions: Part A: Placebo, Part A: CR845 0.5 mcg/kg, Part A: CR845 1.0 mcg/kg, Part A: CR845 2.5 mcg/kg, Part B: Placebo, Part B: CR845 1.0 mcg/kg; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 20
States / cities: Pine Bluff, Arkansas • Chula Vista, California • Long Beach, California + 17 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Home Automated Telemanagement (HAT); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Traumatic Brain Injury, Self Efficacy
Interventions: BICS Q; Diagnostic Test
Lead sponsor: Rehabilitation Hospital of Indiana; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pulmonary Hypertension
Interventions: PF-07868489; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: San Francisco, California • New York, New York

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Herpes Simplex
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 30 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 2 more

Conditions: Fragile X Syndrome
Interventions: arbaclofen, Placebo; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 24 more

Conditions: Hypertension, Hyperlipidemias
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes, Cardiovascular Disease
Interventions: TAK-875, TAK-875 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 3,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 218
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more

Conditions: Prostate Cancer
Interventions: Sandostatin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Brain and Central Nervous System Tumors
Interventions: imatinib mesylate, pharmacological study, conventional surgery; Drug · Other · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Steal Syndrome, Chronic Kidney Diseases, Arterio-Venous Fistula
Interventions: DRIL procedure; Procedure
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Hepatic Impairment
Interventions: Mitiperstat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Rialto, California • Hialeah, Florida • Orlando, Florida + 2 more

Conditions: Hereditary Angioedema
Interventions: CSL312; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 11
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 8 more

Conditions: Breast Cancer
Interventions: zafirlukast, Standard of Care (no intervention); Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: COPD, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Severe, Chronic Obstructive Pulmonary Disease Moderate
Interventions: Wellinks; Other
Lead sponsor: Convexity Scientific Inc; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma, Stage II Melanoma, Uveal Melanoma, Mucosal Melanoma, Unresectable Clear Cell Renal Cell Carcinoma
Interventions: Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor, Adult, Solid Tumor Cancer
Interventions: DF6215, pembrolizumab, KEYTRUDA®; Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Diego, California + 5 more

Conditions: HIV Infections
Interventions: Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 27 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Dementia, Alzheimer Disease, Neurodegenerative Diseases
Interventions: A novel digital health device; Device
Lead sponsor: mandy; Industry
Eligibility: Up to 110 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Elk Grove, California • Oakland, California

Conditions: Prediabetic State
Interventions: GlucoSupreme™ Herbal, Placebo; Dietary Supplement · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Multiple System Atrophy
Interventions: HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Interventions: ABT-751, Placebo, Docetaxel; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Burbank, California • Orange, California + 10 more

Search by objective public record fields.

Effects of Bisphosphonates on OI-Related Hearing Loss

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

Effectiveness of Home Automated Telemanagement in Chronic Obstructive Pulmonary Disorder

Brain Injury Self-Efficacy Scale Validation

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease

Herpevac Neonatal Substudy

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Sandostatin for Patients With Androgen Independent Prostate Cancer

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

Hemodynamic Assessment of Distal Revascularization Interval Ligation

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial

Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD

Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy

Study of DF6215 in Patients With Advanced Solid Tumors

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

Assessing a Novel Virtual Environment That Assists With Activities of Daily Living

RCT of a Polyherbal Dietary Supplement for Prediabetes

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer